Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy.
Florentine E F TimmerBart GeboersSanne NieuwenhuizenEvelien A C SchoutenMadelon DijkstraJan J J de VriesM Petrousjka van den TolTanja D de GruijlHester J SchefferMartijn R MeijerinkPublished in: Current oncology reports (2021)
Locoregional percutaneous interventional techniques such as ablation, brachytherapy, and intra-arterial chemotherapy possess cytoreductive abilities and have the potential to increase survival. In addition, recent research demonstrates the immunomodulatory capacities of these treatments. This immune response may be leveraged by combining the interventional techniques with intra-tumoral immunotherapy, possibly creating a durable anti-tumor effect. This multimodality treatment approach is currently being examined in several ongoing clinical trials. The use of certain interventional techniques appears to improve survival in LAPC patients and may work synergistically when combined with immunotherapy. However, definitive conclusions can only be made when large prospective (randomized controlled) trials confirm these results.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- radiation therapy
- squamous cell carcinoma
- phase ii study
- radiofrequency ablation
- immune response
- clinical trial
- end stage renal disease
- randomized controlled trial
- high dose
- minimally invasive
- chronic kidney disease
- ejection fraction
- newly diagnosed
- ultrasound guided
- prognostic factors
- dendritic cells
- patient reported outcomes
- risk assessment
- toll like receptor
- study protocol
- phase ii
- open label